Ristimäki Ari, Kytölä Soili, Haglund Caj, Bono Petri
Duodecim. 2013;129(10):1071-9.
Cancer diseases are treated with targeted drugs utilizing several distinct mechanisms of action. The decision about targeted therapy will result from multiprofessional collaboration based on a representative biopsy, precise morphological diagnosis, elucidation of the extent of the disease and reliable methods of molecular analysis. Changes at the molecular level are determined by immunohistochemical stainings indicating the expression of proteins and by cytogenetic and molecular genetic tests. When successful, the clinical decision provides the cancer patient with maximally effective therapy and guarantees that the patient will not be needlessly exposed to ineffective treatment involving side effects.
癌症疾病采用具有多种不同作用机制的靶向药物进行治疗。靶向治疗的决策将来自多专业协作，其依据是具有代表性的活检、精确的形态学诊断、疾病范围的阐明以及可靠的分子分析方法。分子水平的变化通过指示蛋白质表达的免疫组织化学染色以及细胞遗传学和分子遗传学检测来确定。若取得成功，临床决策可为癌症患者提供最有效的治疗，并确保患者不会不必要地遭受涉及副作用的无效治疗。
